EMVISION MEDICAL DEVICES LTD - Announcements

3.11%

$1.99

Market Cap $170.1M

Technology Scientific & Technical Instruments

EMVision Medical Devices Limited is an Australian medical device company. The Company is... EMVision Medical Devices Limited is an Australian medical device company. The Company is focused on the development and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, as well as other medical imaging needs. The Company’s primary focus is portable and non-invasive brain scanners, including a bedside device (emu) and an ultra-light weight pre-hospital device (First Responder). Its first indication is in stroke care. Its product pipeline includes portable and non-invasive brain scanners, including a bedside device (emu) and a light weight first responder pre-hospital device. Its First Responder Brain Scanner device is an ultra-light weight device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients regardless of location. The emu Brain Scanner device detects clinically significant changes, at the bedside, when time matters.More

Actinogen Medical (ASX:ACW) reaches 100th participant milestone in Alzheimer’s Disease Trial & confirms interim analysis timeline.

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

EMV	Appendix 4E & Annual Report to 30 June 2025	PRICE SENSITIVE	28/08/25	1.56MB	Share
EMV	UCLA Health Activation & Continuous Innovation Study Update	PRICE SENSITIVE	26/08/25	325.25KB	Share
EMV	EMVision Awarded $3m Grant For Regional Benefits Study	PRICE SENSITIVE	15/08/25	203.53KB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/07/25	290.37KB	Share
EMV	First Responder Program Advanced & Grant Milestone Achieved	PRICE SENSITIVE	29/07/25	415.53KB	Share
EMV	Key Developments in Pivotal Trial & Innovation Study	PRICE SENSITIVE	02/07/25	541.34KB	Share
EMV	EMVision Awarded $5m Non-Dilutive Government Grant	PRICE SENSITIVE	16/06/25	500.26KB	Share
EMV	Additional Pivotal Trial Site Activations	PRICE SENSITIVE	03/06/25	337.35KB	Share
EMV	Enhanced Algorithm Performance From Continuous Innovation	PRICE SENSITIVE	21/05/25	402.92KB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	284.03KB	Share
EMV	Activation of Second US Pivotal Trial Site, Mayo Clinic	PRICE SENSITIVE	28/04/25	325.6KB	Share
EMV	Emu Pivotal Validation Trial Commences	PRICE SENSITIVE	27/03/25	341.97KB	Share
EMV	First Responder Scanner in Successful Aeromedical Testing	PRICE SENSITIVE	19/03/25	448.9KB	Share
EMV	S&P DJI Announces March 2025 Quarterly Rebalance	PRICE SENSITIVE	07/03/25	174.42KB	Share
EMV	EMVision Releases its FY25 Half Yearly Report	PRICE SENSITIVE	27/02/25	145.95KB	Share
EMV	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/25	794.5KB	Share
EMV	US Ethics Approval Received for Pivotal Validation Trial	PRICE SENSITIVE	12/02/25	187.95KB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/01/25	298.03KB	Share
EMV	EMVision Receives $2.12m R&D Tax Rebate	PRICE SENSITIVE	20/01/25	163.94KB	Share
EMV	Algorithms Deliver Excellent Results In EMView Study	PRICE SENSITIVE	12/11/24	898.25KB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/10/24	281.34KB	Share
EMV	EMV Prepares for Trial Following Positive FDA Engagement	PRICE SENSITIVE	29/10/24	237.55KB	Share
EMV	Appendix 4E & Annual Report to 30 June 2024	PRICE SENSITIVE	28/08/24	3.15MB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/07/24	283.43KB	Share
EMV	First Responder Device Unveiled	PRICE SENSITIVE	23/07/24	1.35MB	Share
EMV	Stage 3 Recuitment Achieved & FDA Engagement Underway	PRICE SENSITIVE	08/07/24	458.85KB	Share
EMV	Pilot Production Line Established & $1.25m Grant Received	PRICE SENSITIVE	24/06/24	279.53KB	Share
EMV	Trial data confirms early ischaemia detection capabilities	PRICE SENSITIVE	27/05/24	546.76KB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/04/24	281.83KB	Share
EMV	Stage 2 Insights Confirm Diagnostic & Clinical Viability	PRICE SENSITIVE	27/03/24	503.12KB	Share
EMV	ASA Milestone Achieved for $0.6m Grant Payment	PRICE SENSITIVE	13/03/24	181.09KB	Share
EMV	Half Yearly Report and Accounts	PRICE SENSITIVE	29/02/24	577.51KB	Share
EMV	Strategic A$15.28M Investment from Keysight Technologies	PRICE SENSITIVE	29/02/24	241.94KB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	279.2KB	Share
EMV	EMVision Receives $2.58m R&D Rebate & ASA Milestone Achieved	PRICE SENSITIVE	18/12/23	206.03KB	Share
EMV	Stage 2 Trial Recruitment Tartget Reached & EMU Unveiled	PRICE SENSITIVE	27/11/23	626.35KB	Share
EMV	AGM CEO Presentation including Latest Imaging Case Studies	PRICE SENSITIVE	15/11/23	925.63KB	Share
EMV	AGM Chairman's Address	PRICE SENSITIVE	15/11/23	185.54KB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/23	279.77KB	Share
EMV	Gen 2 Advanced Prototype Assembled	PRICE SENSITIVE	24/10/23	368.06KB	Share
EMV	Encouraging Interim Clinical Trial Results	PRICE SENSITIVE	10/10/23	301.22KB	Share
EMV	Appendix 4E & Annual Report to 30 June 2023	PRICE SENSITIVE	30/08/23	2.65MB	Share
EMV	Latest Imaging and Clinical Trial Insights	PRICE SENSITIVE	22/08/23	439.6KB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/23	278.88KB	Share
EMV	Clinical Trial Progress & ASA Milestone Achieved	PRICE SENSITIVE	27/07/23	296.23KB	Share
EMV	Recruitment at Royal Melbourne Hospital Commences	PRICE SENSITIVE	29/06/23	163.91KB	Share
EMV	$1.75M Manufacturing Grant Payment Received	PRICE SENSITIVE	13/06/23	166.25KB	Share
EMV	Leadership Transition	PRICE SENSITIVE	31/05/23	174.93KB	Share
EMV	Stage 2 of Clinical Trial Activated	PRICE SENSITIVE	29/05/23	305.1KB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/04/23	280KB	Share
EMV	Product Development Milestones & Grant Funding Achieved	PRICE SENSITIVE	17/04/23	332.81KB	Share
EMV	CEO Half-Year Update	PRICE SENSITIVE	28/02/23	191.51KB	Share
EMV	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	602.84KB	Share
EMV	Clinical Trial Stage 1 Enrolment Completed	PRICE SENSITIVE	21/02/23	295.79KB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	284.35KB	Share
EMV	Trial Progressing on Target and ASA Milestone Achieved	PRICE SENSITIVE	25/01/23	197.84KB	Share
EMV	$8.8m In Non-Dilutive Funding To Be Received This Quarter	PRICE SENSITIVE	01/12/22	218.02KB	Share
EMV	EMVision Commences Clinical Trial	PRICE SENSITIVE	30/11/22	192.9KB	Share
EMV	AGM Chairman Address and Presentation	PRICE SENSITIVE	16/11/22	963.15KB	Share
EMV	Portable Brain Scanner Delivered to First Clinical Site	PRICE SENSITIVE	14/11/22	195.25KB	Share
EMV	EMVision Backed By NSW Medical Devices Fund With $2.5m Grant	PRICE SENSITIVE	11/11/22	207.48KB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	307.4KB	Share
EMV	$5m Modern Manufacturing Initiative Funding Agreement Signed	PRICE SENSITIVE	25/10/22	310.3KB	Share
EMV	Ethics Approval Received For Multi-Centre Clinical Trial	PRICE SENSITIVE	04/10/22	315.51KB	Share
EMV	Employee Incentive Plan Issue	PRICE SENSITIVE	16/09/22	166.55KB	Share
EMV	Appendix 4E & Annual Report to 30 June 2022	PRICE SENSITIVE	30/08/22	2.09MB	Share
EMV	$5m Modern Manufacturing Initiative Grant Proceeding	PRICE SENSITIVE	29/08/22	137.66KB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/22	323.36KB	Share
EMV	Centres of Excellence Confirmed as First Two Clinical Sites	PRICE SENSITIVE	12/07/22	181.61KB	Share
EMV	EMVision Achieves First Responder Milestone	PRICE SENSITIVE	27/06/22	304.92KB	Share
EMV	EMVision Awarded $5m Non-Dilutive Funding via MMI Grant	PRICE SENSITIVE	18/05/22	184.73KB	Share
EMV	Trading Halt	PRICE SENSITIVE	16/05/22	261.38KB	Share
EMV	Pause in Trading	PRICE SENSITIVE	16/05/22	117.04KB	Share
EMV	EMVision Secures Strategic Agreement With Keysight	PRICE SENSITIVE	04/05/22	270.57KB	Share
EMV	Trading Halt	PRICE SENSITIVE	02/05/22	585.36KB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	276.94KB	Share
EMV	New Appointments to Clinical Advisory Board	PRICE SENSITIVE	09/03/22	185.38KB	Share
EMV	S&P DJI Announces March 2022 Quarterly Rebalance	PRICE SENSITIVE	04/03/22	175.5KB	Share
EMV	CEO Half-Year Update	PRICE SENSITIVE	24/02/22	208.31KB	Share
EMV	Half Yearly Report and Accounts	PRICE SENSITIVE	24/02/22	782.1KB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/01/22	281.1KB	Share
EMV	EMV Technology to be Presented at Prestigious Conference	PRICE SENSITIVE	09/12/21	159.37KB	Share
EMV	EMVision Receives $3.4m Non-Dilutive Funding this Quarter	PRICE SENSITIVE	08/12/21	188KB	Share
EMV	Clinical Trial Data Drives Confidence for Expanded Studies	PRICE SENSITIVE	30/11/21	254.43KB	Share
EMV	AGM Chairman's Address & Presentation	PRICE SENSITIVE	25/11/21	1.56MB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/21	278.57KB	Share
EMV	FDA Breakthrough Device Application Update	PRICE SENSITIVE	06/10/21	183.3KB	Share
EMV	ASA & EMVision Sign $8m Project Agreement	PRICE SENSITIVE	16/09/21	221.58KB	Share
EMV	Appendix 4E & Annual Report 30 June 2021	PRICE SENSITIVE	31/08/21	5.42MB	Share
EMV	1st Gen Device Successfully Manufactured & Ready for Testing	PRICE SENSITIVE	10/08/21	422.09KB	Share
EMV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/07/21	323.02KB	Share
EMV	EMVision 1st Generation Device Progressing Well	PRICE SENSITIVE	20/07/21	575.16KB	Share
EMV	Clinical Research Partnership Signed with Metro South Health	PRICE SENSITIVE	21/06/21	188.09KB	Share
EMV	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/21	274.6KB	Share
EMV	S&P DJI Announces March 2021 Quarterly Rebalance	PRICE SENSITIVE	12/03/21	183.24KB	Share
EMV	Successful MRFF Bid	PRICE SENSITIVE	02/03/21	396.83KB	Share
EMV	Trading Halt	PRICE SENSITIVE	26/02/21	218.64KB	Share
EMV	Half Year Report & CEO Update	PRICE SENSITIVE	25/02/21	713.78KB	Share
EMV	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/21	263.17KB	Share
EMV	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/20	269.69KB	Share

EMV Appendix 4E & Annual Report to 30 June 2025
28/08/25	PRICE SENSITIVE	1.56MB	Share
EMV UCLA Health Activation & Continuous Innovation Study Update
26/08/25	PRICE SENSITIVE	325.25KB	Share
EMV EMVision Awarded $3m Grant For Regional Benefits Study
15/08/25	PRICE SENSITIVE	203.53KB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
30/07/25	PRICE SENSITIVE	290.37KB	Share
EMV First Responder Program Advanced & Grant Milestone Achieved
29/07/25	PRICE SENSITIVE	415.53KB	Share
EMV Key Developments in Pivotal Trial & Innovation Study
02/07/25	PRICE SENSITIVE	541.34KB	Share
EMV EMVision Awarded $5m Non-Dilutive Government Grant
16/06/25	PRICE SENSITIVE	500.26KB	Share
EMV Additional Pivotal Trial Site Activations
03/06/25	PRICE SENSITIVE	337.35KB	Share
EMV Enhanced Algorithm Performance From Continuous Innovation
21/05/25	PRICE SENSITIVE	402.92KB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	284.03KB	Share
EMV Activation of Second US Pivotal Trial Site, Mayo Clinic
28/04/25	PRICE SENSITIVE	325.6KB	Share
EMV Emu Pivotal Validation Trial Commences
27/03/25	PRICE SENSITIVE	341.97KB	Share
EMV First Responder Scanner in Successful Aeromedical Testing
19/03/25	PRICE SENSITIVE	448.9KB	Share
EMV S&P DJI Announces March 2025 Quarterly Rebalance
07/03/25	PRICE SENSITIVE	174.42KB	Share
EMV EMVision Releases its FY25 Half Yearly Report
27/02/25	PRICE SENSITIVE	145.95KB	Share
EMV Half Yearly Report and Accounts
27/02/25	PRICE SENSITIVE	794.5KB	Share
EMV US Ethics Approval Received for Pivotal Validation Trial
12/02/25	PRICE SENSITIVE	187.95KB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
28/01/25	PRICE SENSITIVE	298.03KB	Share
EMV EMVision Receives $2.12m R&D Tax Rebate
20/01/25	PRICE SENSITIVE	163.94KB	Share
EMV Algorithms Deliver Excellent Results In EMView Study
12/11/24	PRICE SENSITIVE	898.25KB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
30/10/24	PRICE SENSITIVE	281.34KB	Share
EMV EMV Prepares for Trial Following Positive FDA Engagement
29/10/24	PRICE SENSITIVE	237.55KB	Share
EMV Appendix 4E & Annual Report to 30 June 2024
28/08/24	PRICE SENSITIVE	3.15MB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
30/07/24	PRICE SENSITIVE	283.43KB	Share
EMV First Responder Device Unveiled
23/07/24	PRICE SENSITIVE	1.35MB	Share
EMV Stage 3 Recuitment Achieved & FDA Engagement Underway
08/07/24	PRICE SENSITIVE	458.85KB	Share
EMV Pilot Production Line Established & $1.25m Grant Received
24/06/24	PRICE SENSITIVE	279.53KB	Share
EMV Trial data confirms early ischaemia detection capabilities
27/05/24	PRICE SENSITIVE	546.76KB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
24/04/24	PRICE SENSITIVE	281.83KB	Share
EMV Stage 2 Insights Confirm Diagnostic & Clinical Viability
27/03/24	PRICE SENSITIVE	503.12KB	Share
EMV ASA Milestone Achieved for $0.6m Grant Payment
13/03/24	PRICE SENSITIVE	181.09KB	Share
EMV Half Yearly Report and Accounts
29/02/24	PRICE SENSITIVE	577.51KB	Share
EMV Strategic A$15.28M Investment from Keysight Technologies
29/02/24	PRICE SENSITIVE	241.94KB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	279.2KB	Share
EMV EMVision Receives $2.58m R&D Rebate & ASA Milestone Achieved
18/12/23	PRICE SENSITIVE	206.03KB	Share
EMV Stage 2 Trial Recruitment Tartget Reached & EMU Unveiled
27/11/23	PRICE SENSITIVE	626.35KB	Share
EMV AGM CEO Presentation including Latest Imaging Case Studies
15/11/23	PRICE SENSITIVE	925.63KB	Share
EMV AGM Chairman's Address
15/11/23	PRICE SENSITIVE	185.54KB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
31/10/23	PRICE SENSITIVE	279.77KB	Share
EMV Gen 2 Advanced Prototype Assembled
24/10/23	PRICE SENSITIVE	368.06KB	Share
EMV Encouraging Interim Clinical Trial Results
10/10/23	PRICE SENSITIVE	301.22KB	Share
EMV Appendix 4E & Annual Report to 30 June 2023
30/08/23	PRICE SENSITIVE	2.65MB	Share
EMV Latest Imaging and Clinical Trial Insights
22/08/23	PRICE SENSITIVE	439.6KB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
28/07/23	PRICE SENSITIVE	278.88KB	Share
EMV Clinical Trial Progress & ASA Milestone Achieved
27/07/23	PRICE SENSITIVE	296.23KB	Share
EMV Recruitment at Royal Melbourne Hospital Commences
29/06/23	PRICE SENSITIVE	163.91KB	Share
EMV $1.75M Manufacturing Grant Payment Received
13/06/23	PRICE SENSITIVE	166.25KB	Share
EMV Leadership Transition
31/05/23	PRICE SENSITIVE	174.93KB	Share
EMV Stage 2 of Clinical Trial Activated
29/05/23	PRICE SENSITIVE	305.1KB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
27/04/23	PRICE SENSITIVE	280KB	Share
EMV Product Development Milestones & Grant Funding Achieved
17/04/23	PRICE SENSITIVE	332.81KB	Share
EMV CEO Half-Year Update
28/02/23	PRICE SENSITIVE	191.51KB	Share
EMV Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	602.84KB	Share
EMV Clinical Trial Stage 1 Enrolment Completed
21/02/23	PRICE SENSITIVE	295.79KB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	284.35KB	Share
EMV Trial Progressing on Target and ASA Milestone Achieved
25/01/23	PRICE SENSITIVE	197.84KB	Share
EMV $8.8m In Non-Dilutive Funding To Be Received This Quarter
01/12/22	PRICE SENSITIVE	218.02KB	Share
EMV EMVision Commences Clinical Trial
30/11/22	PRICE SENSITIVE	192.9KB	Share
EMV AGM Chairman Address and Presentation
16/11/22	PRICE SENSITIVE	963.15KB	Share
EMV Portable Brain Scanner Delivered to First Clinical Site
14/11/22	PRICE SENSITIVE	195.25KB	Share
EMV EMVision Backed By NSW Medical Devices Fund With $2.5m Grant
11/11/22	PRICE SENSITIVE	207.48KB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	307.4KB	Share
EMV $5m Modern Manufacturing Initiative Funding Agreement Signed
25/10/22	PRICE SENSITIVE	310.3KB	Share
EMV Ethics Approval Received For Multi-Centre Clinical Trial
04/10/22	PRICE SENSITIVE	315.51KB	Share
EMV Employee Incentive Plan Issue
16/09/22	PRICE SENSITIVE	166.55KB	Share
EMV Appendix 4E & Annual Report to 30 June 2022
30/08/22	PRICE SENSITIVE	2.09MB	Share
EMV $5m Modern Manufacturing Initiative Grant Proceeding
29/08/22	PRICE SENSITIVE	137.66KB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
28/07/22	PRICE SENSITIVE	323.36KB	Share
EMV Centres of Excellence Confirmed as First Two Clinical Sites
12/07/22	PRICE SENSITIVE	181.61KB	Share
EMV EMVision Achieves First Responder Milestone
27/06/22	PRICE SENSITIVE	304.92KB	Share
EMV EMVision Awarded $5m Non-Dilutive Funding via MMI Grant
18/05/22	PRICE SENSITIVE	184.73KB	Share
EMV Trading Halt
16/05/22	PRICE SENSITIVE	261.38KB	Share
EMV Pause in Trading
16/05/22	PRICE SENSITIVE	117.04KB	Share
EMV EMVision Secures Strategic Agreement With Keysight
04/05/22	PRICE SENSITIVE	270.57KB	Share
EMV Trading Halt
02/05/22	PRICE SENSITIVE	585.36KB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	276.94KB	Share
EMV New Appointments to Clinical Advisory Board
09/03/22	PRICE SENSITIVE	185.38KB	Share
EMV S&P DJI Announces March 2022 Quarterly Rebalance
04/03/22	PRICE SENSITIVE	175.5KB	Share
EMV CEO Half-Year Update
24/02/22	PRICE SENSITIVE	208.31KB	Share
EMV Half Yearly Report and Accounts
24/02/22	PRICE SENSITIVE	782.1KB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
27/01/22	PRICE SENSITIVE	281.1KB	Share
EMV EMV Technology to be Presented at Prestigious Conference
09/12/21	PRICE SENSITIVE	159.37KB	Share
EMV EMVision Receives $3.4m Non-Dilutive Funding this Quarter
08/12/21	PRICE SENSITIVE	188KB	Share
EMV Clinical Trial Data Drives Confidence for Expanded Studies
30/11/21	PRICE SENSITIVE	254.43KB	Share
EMV AGM Chairman's Address & Presentation
25/11/21	PRICE SENSITIVE	1.56MB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
28/10/21	PRICE SENSITIVE	278.57KB	Share
EMV FDA Breakthrough Device Application Update
06/10/21	PRICE SENSITIVE	183.3KB	Share
EMV ASA & EMVision Sign $8m Project Agreement
16/09/21	PRICE SENSITIVE	221.58KB	Share
EMV Appendix 4E & Annual Report 30 June 2021
31/08/21	PRICE SENSITIVE	5.42MB	Share
EMV 1st Gen Device Successfully Manufactured & Ready for Testing
10/08/21	PRICE SENSITIVE	422.09KB	Share
EMV Quarterly Activities/Appendix 4C Cash Flow Report
30/07/21	PRICE SENSITIVE	323.02KB	Share
EMV EMVision 1st Generation Device Progressing Well
20/07/21	PRICE SENSITIVE	575.16KB	Share
EMV Clinical Research Partnership Signed with Metro South Health
21/06/21	PRICE SENSITIVE	188.09KB	Share
EMV Appendix 4C - quarterly
30/04/21	PRICE SENSITIVE	274.6KB	Share
EMV S&P DJI Announces March 2021 Quarterly Rebalance
12/03/21	PRICE SENSITIVE	183.24KB	Share
EMV Successful MRFF Bid
02/03/21	PRICE SENSITIVE	396.83KB	Share
EMV Trading Halt
26/02/21	PRICE SENSITIVE	218.64KB	Share
EMV Half Year Report & CEO Update
25/02/21	PRICE SENSITIVE	713.78KB	Share
EMV Appendix 4C - quarterly
29/01/21	PRICE SENSITIVE	263.17KB	Share
EMV Appendix 4C - quarterly
30/10/20	PRICE SENSITIVE	269.69KB	Share

REFRESH

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.99		Change 0.060(3.11%)		Mkt cap ! $170.1M

Open	High	Low	Value	Volume
$1.92	$2.01	$1.92	$83.25K	42.04K

Buyers (Bids)

No.	Vol.	Price($)
1	6	$1.99

Sellers (Offers)

Price($)	Vol.	No.
$2.01	5902	1

View Market Depth

No.	Vol.	Price($)
1	1000	1.980
1	1382	1.975
2	8052	1.970
1	4000	1.960
1	12000	1.900

Price($)	Vol.	No.
2.010	5902	1
2.020	10000	1
2.040	1960	1
2.060	3136	1
2.080	23312	1

Last trade - 16.10pm 05/09/2025 (20 minute delay)

EMV (ASX) Chart

EMVISION MEDICAL DEVICES LTD - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories